Sanofi (SAN1 N) Stock Overview
Engages in the research, development, manufacture, and marketing of therapeutic solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
SAN1 N Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1,884.93 |
| 52 Week High | €2,153.45 |
| 52 Week Low | €1,760.71 |
| Beta | 0.44 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 23.04% |
| 5 Year Change | n/a |
| Change since IPO | -8.14% |
Recent News & Updates
Recent updates
Shareholder Returns
| SAN1 N | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.003% |
| 1Y | n/a | -14.1% | 10.8% |
Return vs Industry: Insufficient data to determine how SAN1 N performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SAN1 N performed against the MX Market.
Price Volatility
| SAN1 N volatility | |
|---|---|
| SAN1 N Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in MX Market | 5.8% |
| 10% least volatile stocks in MX Market | 2.2% |
Stable Share Price: SAN1 N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine SAN1 N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 82,878 | Paul Hudson | www.sanofi.com |
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepatitis A, typhoid, yellow fever, and rabies vaccines.
Sanofi Fundamentals Summary
| SAN1 N fundamental statistics | |
|---|---|
| Market cap | Mex$2.28t |
| Earnings (TTM) | Mex$137.82b |
| Revenue (TTM) | Mex$987.57b |
Is SAN1 N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAN1 N income statement (TTM) | |
|---|---|
| Revenue | €45.74b |
| Cost of Revenue | €13.12b |
| Gross Profit | €32.62b |
| Other Expenses | €26.24b |
| Earnings | €6.38b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 24, 2025
| Earnings per share (EPS) | 5.25 |
| Gross Margin | 71.32% |
| Net Profit Margin | 13.96% |
| Debt/Equity Ratio | 29.2% |
How did SAN1 N perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 04:25 |
| End of Day Share Price | 2025/09/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sanofi is covered by 72 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |